Apexium Financial’s Boston Scientific BSX Stock Holding History

Apexium Financial’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,897	Closed	-$204K	–	289
2025 Q2	$204K	Buy	+1,897	New	+$192K	0.01%	270

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Apexium Financial's BSX Position: Q3 2025 in Review

Apexium Financial sold out of Boston Scientific (BSX) in Q3 2025, closing a stake of 1,897 shares — an estimated $204K sold.

Apexium Financial first reported a position in BSX in Q2 2025 and held it in 1 quarter. The position peaked at $204K in Q2 2025. 1,708 funds tracked by Wall St. Rank hold BSX as of Q3 2025.

Apexium Financial reported no remaining Boston Scientific position as of Q3 2025 after selling out during the quarter.
Apexium Financial sold 1,897 Boston Scientific shares in Q3 2025, an estimated $204K.
Apexium Financial first reported a position in Boston Scientific in Q2 2025 and held it in 1 quarter.
Apexium Financial's Boston Scientific position peaked at $204K in Q2 2025.
1,708 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2025.

Based on Apexium Financial's 13F filing for Q3 2025, filed 18 Nov 2025.